IL306063A - Preparations and methods for the treatment of neurological diseases - Google Patents
Preparations and methods for the treatment of neurological diseasesInfo
- Publication number
- IL306063A IL306063A IL306063A IL30606323A IL306063A IL 306063 A IL306063 A IL 306063A IL 306063 A IL306063 A IL 306063A IL 30606323 A IL30606323 A IL 30606323A IL 306063 A IL306063 A IL 306063A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- neurologic diseases
- treating neurologic
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163546P | 2021-03-19 | 2021-03-19 | |
| PCT/US2022/020687 WO2022197885A1 (en) | 2021-03-19 | 2022-03-17 | Compositions and methods for treating neurologic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL306063A true IL306063A (en) | 2023-11-01 |
Family
ID=83320987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL306063A IL306063A (en) | 2021-03-19 | 2022-03-17 | Preparations and methods for the treatment of neurological diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240165077A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4308565A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024510249A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230159546A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117355525A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022239497A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3212092A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL306063A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023010831A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022197885A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
| WO2026064542A1 (en) * | 2024-09-18 | 2026-03-26 | Cognition Therapeutics, Inc. | 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms |
| WO2026119142A1 (zh) * | 2024-12-03 | 2026-06-11 | 浙江径科医药有限公司 | 一种氘代异吲哚啉化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| WO2013029057A2 (en) * | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| WO2015116923A1 (en) * | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| US20200000822A1 (en) * | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| ES3063712T3 (en) * | 2017-05-15 | 2026-04-20 | Cognition Therapeutics Inc | Compositions for treating neurodegenerative diseases |
| US20200338045A1 (en) * | 2017-11-01 | 2020-10-29 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| JP2022537581A (ja) * | 2019-06-21 | 2022-08-26 | クラリス コーポレーション | Ppm1阻害剤およびその使用方法 |
| CN110283082A (zh) * | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
-
2022
- 2022-03-17 CA CA3212092A patent/CA3212092A1/en active Pending
- 2022-03-17 US US18/280,565 patent/US20240165077A1/en not_active Abandoned
- 2022-03-17 MX MX2023010831A patent/MX2023010831A/es unknown
- 2022-03-17 EP EP22772183.4A patent/EP4308565A4/en active Pending
- 2022-03-17 JP JP2023556900A patent/JP2024510249A/ja active Pending
- 2022-03-17 CN CN202280035073.7A patent/CN117355525A/zh active Pending
- 2022-03-17 WO PCT/US2022/020687 patent/WO2022197885A1/en not_active Ceased
- 2022-03-17 KR KR1020237035979A patent/KR20230159546A/ko active Pending
- 2022-03-17 AU AU2022239497A patent/AU2022239497A1/en active Pending
- 2022-03-17 IL IL306063A patent/IL306063A/en unknown
-
2026
- 2026-02-04 US US19/529,760 patent/US20260166006A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117355525A (zh) | 2024-01-05 |
| AU2022239497A1 (en) | 2023-09-21 |
| EP4308565A4 (en) | 2025-01-01 |
| WO2022197885A1 (en) | 2022-09-22 |
| KR20230159546A (ko) | 2023-11-21 |
| MX2023010831A (es) | 2023-09-27 |
| US20240165077A1 (en) | 2024-05-23 |
| US20260166006A1 (en) | 2026-06-18 |
| CA3212092A1 (en) | 2022-09-22 |
| EP4308565A1 (en) | 2024-01-24 |
| JP2024510249A (ja) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202207394B (en) | Compositions and methods for treating hemoglobinopathies | |
| IL286350A (en) | Preparations and methods for the treatment of cancer | |
| IL288914A (en) | Preparations and methods for the treatment of cancer | |
| ZA202104870B (en) | Methods and compositions for treating cancer | |
| PT3861985T (pt) | Composições e métodos para tratar doenças oculares | |
| IL285886A (en) | Preparations and methods for the treatment of laminopathy | |
| SG11202011151VA (en) | Compositions and methods for reducing spliceopathy and treating rna dominance disorders | |
| IL285796A (en) | Methods and preparations for the treatment of cancer | |
| EP4308565A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
| IL287982A (en) | Preparations and methods for the treatment of cancer | |
| SG11202010089QA (en) | Compositions and methods for treatment of iron overload | |
| IL304404A (en) | Compositions and methods for treating hereditary angioedema | |
| IL299295A (en) | Methods and compositions for treating hemophilia | |
| EP3768095A4 (en) | Compositions and methods for treating diarrheal diseases | |
| IL315800A (en) | Preparations and methods for the treatment of cancer | |
| EP4352079A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEUROFIBROMATIC DISORDERS | |
| EP4175978A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CRP-MEDIATED DISEASES | |
| IL286153A (en) | Methods and preparations for the treatment of cancer | |
| IL309120A (en) | Methods and compositions for the treatment of cancer | |
| IL309071A (en) | Methods and compositions for the treatment of cancer | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| IL287538A (en) | Preparations and methods for the treatment of cancer | |
| IL288563A (en) | Ethods and compositions for treating autoimmune diseases | |
| IL326065A (en) | Methods of treating medical conditions and diseases |